Although anti-inflammatory therapies such as canakinumab, colchicine, and steroids have shown ability to attenuate NLRP3-mediated inflammation, studies evaluating their role in the treatment and prevention of AF are limited20 (Table 1, Figure 2). This evidence concerns the gene NLRP3 and atrial fibrillation.